Biomarkers evaluation in multiple sclerosis - Frédérique Michel, 2018

Type I Interferon b is commonly prescribed as first-line therapyof relapsing-remitting multiple sclerosis (RR-MS). Yet recent studies have associated a 'type I IFN signature' with some autoimmune diseases, inflammation and chronic immune activation. It is therefore necessary to better define the boundary of the therapeutic and damaging effects of type I IFN and to investigate new disease biomarkers candidates.

Objectives are to evaluate whether IFN a and IFN b measured in plasma and CSF correlate with disease progression and relapse episodes and determine microRNA signatures of resting CD4⁺and CD8⁺T cell subsets, and the impact of IFN b on T cell receptor (TCR)-activated CD4⁺ T cells in patients with a high disease score.